



Accelerating treatments for rare diseases

AI-powered, patient-inspired



The problem

Rare disease patients



7,000 rare diseases



400m patients worldwide



50% are children



Pharma companies rely on blockbuster drugs

R&D costs \$2-3bn



Takes 12-14 years



Success rate of 5%




95% of rare diseases don't have an approved treatment

Mission is simple:

**100 rare disease treatments
towards the clinic by 2025**

AI-powered biotech

Healx repurposes and combines existing drugs using AI to find novel rare disease treatments at scale



Healx redefines and de-risks drug discovery

Traditional drug discovery process



Drug repurposing with Healx



Healx therapeutic pipeline has 10-fold lower attrition rate

The solution

100 rare disease treatments
towards the clinic by 2025

Develop treatments for rare diseases
by using repurposing:



Faster



Cheaper



Safer

AI-powered drug
repurposing


3-5 years



\$50m



25%



Conventional
drug discovery


12-14 years



\$2-3bn



5%




Millions of rare disease patients will have an approved
treatment for the first time



Healnet

AI-powered drug discovery


Healnet: from data to drugs





Therapeutic pipeline

Current projects





The team

Leadership team



Kate Hilyard, PhD

Chief Operating Officer

Senior discovery leadership roles in CRL, Cambridge Antibody Technology and Roche

Over 25 years' drug discovery experience, 10 years' rare disease experience



Tim Guilliams, PhD

Co-founder,
Chief Executive

Founding Director, Trustee,
Cambridge Rare Disease Network
Cambridge University Graduate
PhD in Biophysics



Neil Thompson, PhD

Chief Scientific Officer

Former SVP of Biology at
Astex with over 30 years' drug
discovery experience

Progressed more than 10
drugs into patients across a
variety of therapeutic areas



Ian Roberts, PhD

Chief Technology Officer

Tech leadership roles in
multiple genomics biotech
startups

Over 20 years' experience in
genomic technologies, strong
background in rare cancers



Andrea Pierleoni, PhD

Head of AI

Strong background in NLP,
full-stack dev & knowledge
graph reasoning

Lead back end architect,
Open Targets

PhD in computational biology



Bruce Bloom

Chief Collaboration Officer

Founder, CEO and CSO of non-
profit Cures Within Reach

Extensive patient group and
charity partnership involvement
and over 40 years' healthcare
industry experience

Board of directors



Jonathan Milner

Investor Director

Co-founder, Abcam
Co-founder, Milner Institute
for Therapeutics



David Brown

Chairman, Founding
Director

Ex-Global Head Drug
Discovery, Roche
Co-inventor of Viagra



**Suranga
Chandratillake**

Investor Director

Partner, Balderton Capital
Founder and CEO of Blinkx
Former CTO Autonomy



Shaun Grady

Board Director

Global VP, Business
Development Operations,
AstraZeneca
Led Medimmune
acquisition



Irina Haivas

Board Member

Principal at Atomico
Former strategy consultant at
Bain & Co. and growth and PE
investor at GHQ Capital



Tim Guilliams

Founding Director

Founding Director, Trustee,
Cambridge Rare Disease Network
Cambridge University Graduate
PhD in Biophysics

